Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014
Cheraghlou S, Schettino A, Zogg CK, Judson BL. Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014. The Laryngoscope 2018, 128: 2762-2769. PMID: 30194691, DOI: 10.1002/lary.27315.Peer-Reviewed Original ResearchConceptsOral cavity cancerLate-stage diseaseAdjuvant therapyOral cancerEnd Results 9 registriesCox survival regressionHigher nodal yieldsNational Cancer DatabaseEarly-stage diseaseKaplan-Meier analysisRetrospective database analysisAnalysis of survivalAdjuvant chemoradiotherapyNodal yieldAdult patientsNeck dissectionRetrospective studyCancer DatabasePrognosisPatientsCancerDiseaseDatabase analysisSurvival regressionChemoradiotherapyManagement of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy 2018, 67: 1833-1844. PMID: 30191256, PMCID: PMC6249064, DOI: 10.1007/s00262-018-2241-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalComorbidityDisease ManagementFemaleHealth Care SurveysHumansImmunotherapyMaleMelanomaMiddle AgedMolecular Targeted TherapyNeoplasm StagingOdds RatioProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRegistriesSymptom AssessmentUnited StatesYoung AdultConceptsStage 4 melanomaOverall survivalInitial approvalCutaneous melanomaLandmark survival analysisSubstantial clinical efficacyImproved overall survivalMetastatic cutaneous melanomaNational Cancer DatabaseStage 4 diseaseCheckpoint blockade immunotherapySurvival of patientsRisk-adjusted analysisBlockade immunotherapyCheckpoint blockadeNovel immunotherapiesMultivariable analysisClinical efficacyMetastatic melanomaNational cohortCancer DatabaseUninsured patientsClinical trialsPatientsSurvival analysisImproved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research 2018, 6: 1039-1045. PMID: 30002157, PMCID: PMC6230261, DOI: 10.1158/2326-6066.cir-18-0067.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesCheckpoint blockade immunotherapyMBM patientsOverall survivalBlockade immunotherapyStage 4 melanomaNational Cancer DatabaseManagement of patientsKaplan-Meier techniqueLarge national cohortEarly clinical trialsBrain metastasesExtracranial metastasesSurvival benefitAdvanced melanomaOS improvementNational cohortCancer DatabaseClinical trialsNovel therapiesU.S. cancerPatientsTherapy trialsProportional hazardsFDA approvalAdjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma
Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma. The Laryngoscope 2018, 129: 883-889. PMID: 30151947, DOI: 10.1002/lary.27444.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Squamous CellChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSalivary Gland NeoplasmsSurvival RateTreatment OutcomeConceptsLate-stage patientsSquamous cell carcinomaAdjuvant radiotherapyAdjuvant therapyAdjuvant chemoradiotherapyAdjuvant chemotherapyImproved survivalCell carcinomaImproved long-term survivalCox survival regressionPrimary cutaneous malignanciesUnique disease entityAddition of chemotherapyNational Cancer DatabaseEarly-stage diseaseFive-year survivalEarly-stage patientsKaplan-Meier analysisParotid gland cancerLate stage groupLong-term survivalSurvival benefitCutaneous malignanciesPoor prognosisRetrospective studyEthnic disparity in primary cutaneous CD30+ T‐cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database
Su C, Nguyen KA, Bai HX, Zogg CK, Cao Y, Karakousis G, Zhang PJ, Zhang G, Xiao R. Ethnic disparity in primary cutaneous CD30+ T‐cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database. British Journal Of Haematology 2018, 181: 752-759. PMID: 29676444, DOI: 10.1111/bjh.15222.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedDatabases, FactualDisease-Free SurvivalFemaleFollow-Up StudiesHead and Neck NeoplasmsHumansKi-1 AntigenLymphoproliferative DisordersMaleMiddle AgedNeoplasm ProteinsRetrospective StudiesSex FactorsSkin NeoplasmsSocioeconomic FactorsSurvival RateT-LymphocytesUnited StatesConceptsT-cell lymphoproliferative disorderUS National Cancer DatabaseNational Cancer DatabasePrimary cutaneous CD30Overall survivalShorter overall survivalCutaneous CD30AA patientsLymphoproliferative disordersDisease characteristicsCancer DatabaseCutaneous T-cell lymphoma casesCox proportional hazards regression analysisPrimary cutaneous T-cell lymphomaEthnic disparitiesHigher Charlson-Deyo scoreProportional hazards regression analysisCutaneous T-cell lymphomaT-cell lymphoma casesCharlson-Deyo scorePrimary disease siteReceipt of chemotherapyHazards regression analysisSmall retrospective studiesHigher clinical stage